Back to Journals » Therapeutics and Clinical Risk Management » Volume 2 » Issue 3

Oxycodone controlled release in cancer pain management

Authors Giuseppe Biancofiore

Published 15 September 2006 Volume 2006:2(3) Pages 229—234

Giuseppe Biancofiore



Department of Medical Oncology and Hematology, Istituto Clinico Humanitas, Rozzano (MI), Italy



Abstract: Oral opioids are the treatment of choice for chronic cancer pain. Morphine is the strong opioid of choice for the treatment of moderate to severe cancer pain according to guidelines from the World Health Organization (WHO). This recommendation by the WHO was derived from availability, familiarity to clinicians, established effectiveness, simplicity of administration, and relative inexpensive cost. It was not based on proven therapeutic superiority over other options. Patients who experience inadequate pain relief or intolerable side effects with one opioid may often be successfully treated with another agent or with the same agent administered by a different route. Opioid rotation, or switching to an alternative opioid, helps some patients achieve better pain control with fewer associated adverse effects. Oxycodone is a µ-opioid receptor specific ligand, with clear agonist properties. It is an active potent opioid, which is in part a κ-receptor agonist. Like morphine and other pure agonists, there is no known ceiling to the analgesic effects of oxycodone. The active metabolites of oxycodone (eg, oxymorphone) could be important in oxycodone-mediated analgesia. The main pharmacokinetic difference between oxycodone and morphine is in oral bioavailability. The bioavailability of oxycodone is >60% and the bioavailability of morphine is 20%. Controlled-release oxycodone is absorbed in a bi-exponential fashion. There is a rapid phase with a mean half-life of 37 min, accounting for 38% of the dose, and a slow phase with a halflife of 6.2 h, which accounts for the residual 62%. Oxycodone elimination is impaired by renal failure because there are both an increased volume of distribution and reduced clearance. A lot of studies prove that the efficacy of controlled-release oxycodone in cancer-pain control is at least the same as morphine, immediate-release oxycodone and hydromorphone. Its toxicity profile seems better than that of morphine. There are actually several illustrations of a lower incidence of side-effects in the central nervous system. It is therefore possible to conclude that oxycodone represents a valid alternative to morphine in the management of moderate to severe cancer pain, also as first-line treatment.



Keywords: oxycodone, opioids, cancer pain, analgesic, morphine

Download Article [PDF] 

Readers of this article also read:

Vinflunine in the treatment of bladder cancer

Mark Bachner, Maria De Santis

Therapeutics and Clinical Risk Management 2008, 4:1243-1253

Published Date: 5 December 2008

Treatment of severe psoriasis with infliximab

JA Leman, AD Burden

Therapeutics and Clinical Risk Management 2008, 4:1165-1175

Published Date: 5 December 2008

Treatment strategies in mucous membrane pemphigoid

Ann G Neff, Matthew Turner, Diya F Mutasim

Therapeutics and Clinical Risk Management 2008, 4:617-626

Published Date: 6 June 2008

Concurrent Chagas’ disease and borderline disseminated cutaneous leishmaniasis: The role of amiodarone as an antitrypanosomatidae drug

Alberto E Paniz-Mondolfi, Alexandra M Pérez-Álvarez, Oscar Reyes-Jaimes, Gustavo Socorro, Olga Zerpa, et al

Therapeutics and Clinical Risk Management 2008, 4:659-663

Published Date: 6 June 2008

Multiple sclerosis presented as clinically isolated syndrome: the need for early diagnosis and treatment

Sigliti-Henrietta Pelidou, Sotirios Giannopoulos, Sotiria Tzavidi, Georgios Lagos, Athanassios P Kyritsis

Therapeutics and Clinical Risk Management 2008, 4:627-630

Published Date: 6 June 2008

Reflections on adjuvant treatment of gastric cancer

Albert Abad, José Luis Manzano, Cristina Martí

Therapeutics and Clinical Risk Management 2007, 3:563-567

Published Date: 15 September 2007